Medtronic: Solid Quarter but Limited Growth Visibility Justifies Hold Rating

Medtronic, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Danielle Antalffy from UBS maintained a Hold rating on the stock and has a $104.00 price target.

Danielle Antalffy has given his Hold rating due to a combination of factors related to Medtronic’s recent performance and outlook. While the company delivered quarterly sales and earnings above consensus, growth in key segments such as medical surgical and neuroscience fell short of expectations, and overall 6% organic growth was seen as merely meeting, rather than exceeding, the buyside’s minimum hurdle.

At the same time, management only reaffirmed guidance instead of raising it, implying no meaningful acceleration in organic growth despite high investor expectations and signs of slowing momentum outside the high‑growth CAS franchise. With capacity constraints likely limiting further upside in ablation procedures and uncertainty around how fast new products like Symplicity and AltaViva can ramp to offset potential CAS deceleration, Antalffy prefers to remain on the sidelines until there is clearer evidence of sustainable upside to both revenue and EPS.

According to TipRanks, Antalffy is a 4-star analyst with an average return of 2.8% and a 50.53% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Inspire Medical Systems, and Medtronic.

In another report released yesterday, TipRanks – Anthropic also downgraded the stock to a Hold with a $108.00 price target.